Liberty Wealth Management LLC boosted its position in Allergan plc (NYSE:AGN) by 35.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257 shares of the company’s stock after buying an additional 67 shares during the quarter. Liberty Wealth Management LLC’s holdings in Allergan were worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of AGN. FMR LLC boosted its stake in Allergan by 42.0% in the first quarter. FMR LLC now owns 6,042,005 shares of the company’s stock worth $884,611,000 after buying an additional 1,788,265 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Allergan by 27.6% in the first quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock worth $857,312,000 after buying an additional 1,265,742 shares in the last quarter. Ellis Investment Partners LLC boosted its stake in Allergan by 14,302.8% in the first quarter. Ellis Investment Partners LLC now owns 852,214 shares of the company’s stock worth $852,000 after buying an additional 846,297 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Allergan by 8.6% in the first quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after buying an additional 726,688 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in Allergan by 6.5% in the first quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after buying an additional 410,746 shares in the last quarter. 79.95% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on AGN shares. UBS Group cut their target price on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Jefferies Financial Group started coverage on Allergan in a research note on Monday, April 15th. They set a “hold” rating and a $144.95 price objective for the company. JPMorgan Chase & Co. set a $200.00 price objective on Allergan and gave the company a “buy” rating in a research note on Wednesday, June 19th. Sanford C. Bernstein lowered Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective for the company. in a research note on Tuesday, July 16th. Finally, Leerink Swann lowered Allergan from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $217.00 to $188.00 in a research note on Thursday, July 18th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $180.00.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company had revenue of $4.09 billion during the quarter, compared to analyst estimates of $3.93 billion. During the same quarter last year, the firm posted $4.42 earnings per share. The firm’s revenue was down .8% on a year-over-year basis. On average, equities analysts expect that Allergan plc will post 16.64 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date is Monday, August 12th. Allergan’s payout ratio is 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
See Also: What is a Lock-Up Period?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.